MOUSE ANTI RAT CD4 (DOMAIN 1) Azide Free

Price:
1056 EUR
1267 USD
876 GBP
known as: MOUSE ANTI RAT CD4 (DOMAIN 1) Azide Free
Catalog number: genta-ABS0351
Product Quantity: 1 mg
Category:
Supplier: AbD

   CAPTCHA Image   Reload Image

Gene target: cd4 domain 1

Related genes to: MOUSE ANTI RAT CD4 (DOMAIN 1) Azide Free

Symbol : cd4 NIH gene
description : T-cell surface glycoprotein CD4
type of gene : protein-coding
Modification date : 2015-09-26

Related Pathways to: MOUSE ANTI RAT CD4 (DOMAIN 1) Azide Free

Gene about :domain
Pathway :Dm Notch Signaling Pathway
domain
Gene about :Cd4
Pathway :Rn Cytokines and Inflammatory Response (BioCarta)
Cd4

Related product to: MOUSE ANTI RAT CD4 (DOMAIN 1) Azide Free

Related Articles about: MOUSE ANTI RAT CD4 (DOMAIN 1) Azide Free

Differential Requirements for Tcf1 Long Isoforms in CD8(+) and CD4(+) T Cell Responses to Acute Viral Infection.

In response to acute viral infection, activated naive T cells give rise to effector T cells that clear the pathogen and memory T cells that persist long-term and provide heightened protection. T cell factor 1 (Tcf1) is essential for several of these differentiation processes. Tcf1 is expressed in multiple isoforms, with all isoforms sharing the same HDAC and DNA-binding domains and the long isoforms containing a unique N-terminal β-catenin-interacting domain. In this study, we specifically ablated Tcf1 long isoforms in mice, while retaining expression of Tcf1 short isoforms. During CD8(+) T cell responses, Tcf1 long isoforms were dispensable for generating cytotoxic CD8(+) effector T cells and maintaining memory CD8(+) T cell pool size, but they contributed to optimal maturation of central memory CD8(+) T cells and their optimal secondary expansion in a recall response. In contrast, Tcf1 long isoforms were required for differentiation of T follicular helper (TFH) cells, but not TH1 effectors, elicited by viral infection. Although Tcf1 short isoforms adequately supported Bcl6 and ICOS expression in TFH cells, Tcf1 long isoforms remained important for suppressing the expression of Blimp1 and TH1-associated genes and for positively regulating Id3 to restrain germinal center TFH cell differentiation. Furthermore, formation of memory TH1 and memory TFH cells strongly depended on Tcf1 long isoforms. These data reveal that Tcf1 long and short isoforms have distinct, yet complementary, functions and may represent an evolutionarily conserved means to ensure proper programming of CD8(+) and CD4(+) T cell responses to viral infection. - Source :PubMed

Potent inhibition of HIV-1 replication in resting CD4 T cells by resveratrol and pterostilbene.

HIV-1 infection of resting CD4 T cells plays a crucial and numerically dominant role during virus transmission at mucosal sites and during subsequent acute replication and T cell depletion. Resveratrol and pterostilbene are plant stilbenoids associated with several health promoting benefits. Resveratrol has been shown to inhibit replication of several viruses, including herpes simplex 1 and 2, papillomaviruses, SARS virus and influenza virus. Alone, resveratrol does not inhibit HIV-1 infection of activated T cells, but it does synergize with nucleoside reverse transcriptase inhibitors in these cells to inhibit reverse transcription. Here, we demonstrate that resveratrol and pterostilbene completely block HIV-1 infection at low micromolar dose in resting CD4 T cells, primarily at the reverse transcription step. The anti-HIV effect was fully reversed by exogenous deoxynucleosides and Vpx, a simian immunodeficiency virus protein that increases dNTP levels. These findings are consistent with the reported ability of resveratrol to inhibit ribonucleotide reductase and to lower dNTP levels in cells. This study supports the potential use of resveratrol, pterostilbene or related compounds as adjuvants in anti-HIV pre-exposure prophylaxis (PrEP) formulations. - Source :PubMed

Cytokines affecting CD4(+)T regulatory cells in transplant tolerance. III. Interleukin-5 (IL-5) promotes survival of alloantigen-specific CD4(+) T regulatory cells.

CD4(+)T cells mediate antigen-specific allograft tolerance, but die in culture without activated lymphocyte derived cytokines. Supplementation of the media with cytokine rich supernatant, from ConA activated spleen cells, preserves the capacity of tolerant cells to transfer tolerance and suppress rejection. rIL-2 or rIL-4 alone are insufficient to maintain these cells, however. We observed that activation of naïve CD4(+)CD25(+)FOXP3(+)Treg with alloantigen and the Th2 cytokine rIL-4 induces them to express interleukin-5 specific receptor alpha (IL-5Rα) suggesting that IL-5, a Th2 cytokine that is produced later in the immune response may promote tolerance mediating Treg. This study examined if recombinant IL-5(rIL-5) promoted survival of tolerant CD4(+), especially CD4(+)CD25(+)T cells. CD4(+)T cells, from DA rats tolerant to fully allogeneic PVG heart allografts surviving over 100days without on-going immunosuppression, were cultured with PVG alloantigen and rIL-5. The ability of these cells to adoptively transfer tolerance to specific-donor allograft and suppress normal CD4(+)T cell mediated rejection in adoptive DA hosts was examined. Tolerant CD4(+)CD25(+)T cells' response to rIL-5 and expression of IL-5Rα was also assessed. rIL-5 was sufficient to promote transplant tolerance mediating CD4(+)T cells' survival in culture with specific-donor alloantigen. Tolerant CD4(+)T cells cultured with rIL-5 retained the capacity to transfer alloantigen-specific tolerance and inhibited naïve CD4(+)T cells' capacity to effect specific-donor graft rejection. rIL-5 promoted tolerant CD4(+)CD25(+)T cells' proliferation in vitro when stimulated with specific-donor but not third-party stimulator cells. Tolerant CD4(+)CD25(+)T cells expressed IL-5Rα. This study demonstrated that IL-5 promoted the survival of alloantigen-specific CD4(+)CD25(+)T cells that mediate transplant tolerance. - Source :PubMed

The CD4+ T cell regulatory network mediates inflammatory responses during acute hyperinsulinemia: a simulation study.

Obesity is frequently linked to insulin resistance, high insulin levels, chronic inflammation, and alterations in the behaviour of CD4+ T cells. Despite the biomedical importance of this condition, the system-level mechanisms that alter CD4+ T cell differentiation and plasticity are not well understood. - Source :PubMed

Expression of Th17 and CD4+ CD25+ T regulatory cells in peripheral blood of acute leukemia patients and their prognostic significance.

To discuss the expression of T helper cell 17 (Th17) cells and CD4+ CD25+ Foxp3+ regulatory T cells (Treg) in peripheral blood (PB) of patients with acute leukemia (AL), and to explore the relationship between them and disease prognosis. 40 patients diagnosed with acute leukemia in The First Affiliated Hospital of Zhengzhou University from July 2012 to August 2014 were selected as the observation group. Meanwhile, 40 healthy people were taken as the control group. Flow Cytometry Method (FCM) was used to detect the level of Th17 cells and CD4(+) CD25(+) Foxp3(+) cells in peripheral blood of the two groups, and enzyme-linked immuno sorbent assay (ELISA) method was used to test the level of IL17 and TGF-β in peripheral blood of two groups; reverse transcription-polymerase chain reaction (RT-PCR) was adopted to analyze the mRNA levels of RORγT and Foxp3 in peripheral blood. In addition, we examined the levels of Th17 and CD4(+) CD25(+) Foxp3(+) cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51±0.27)%, which was significantly higher than that of control group (0.36±0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4(+) CD25(+) Foxp3(+) cells in AL patients was (3.37±0.48)%, which was significantly higher than that of control group of (1.26±0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-β in AL patients were (28.12±6.33) pg/ml and (38.41±8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41±6.21) pg/ml and (24.49±7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORγT mRNA and Foxp3 mRNA levels in AL patients were all significantly higher than that of control group, with statistical significance (t=12.27, P<0.001; t=7.89, P<0.001). In addition, compared with before chemotherapy, the levels of Th17 cells and CD4(+) CD25(+) Foxp3(+) cells, and the serum levels of IL-17 and TGF-β in acute leukemia patients all decreased significantly after 6 months of chemotherapy, and the difference was statistically significant (P<0.001). Th17 cells, CD4(+) CD25(+) Foxp3(+) cells and their secretory proteins IL-17, TGF-β and transcription factors were significantly increased in AL patients. Therefore, regular detection of peripheral blood Th17 and Treg cells, as well as their secretory proteins are useful for monitoring the immune status and prognosis of patients. - Source :PubMed

Gentaur adresses


GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
france@gentaur.com
dimi@gentaur.com
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531
Fax 020 8445 9411
uk@gentaur.com
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
poland@gentaur.com
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893
Fax 0497-517897
nl@gentaur.com
GENTAUR SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com
GENTAUR bulgaria
53 Iskar Str. Kokalyane,
Sofia 1191
Tel 0035929830070
Fax 0035929830072
sofia@gentaur.com
GENTAUR Spain
Tel 0911876558
spain@gentaur.com
GENTAUR USA
Genprice Inc, Logistics
547 Yurok Circle
San Jose, CA 95123
invoicing/ accounting:
6017 Snell Ave, Suite 357
San Jose, CA. 96123
Tel 001 408 780 0908
jane@gentaur.com